These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24730531)

  • 21. Combined cardioprotectant and antithrombotic actions of platelet P2Y12 receptor antagonists in acute coronary syndrome: just what the doctor ordered.
    Cohen MV; Downey JM
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):179-90. PubMed ID: 24298192
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors.
    Yanachkov IB; Chang H; Yanachkova MI; Dix EJ; Berny-Lang MA; Gremmel T; Michelson AD; Wright GE; Frelinger AL
    Eur J Med Chem; 2016 Jan; 107():204-18. PubMed ID: 26588064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modern antiplatelet agents in coronary artery disease.
    Power RF; Hynes BG; Moran D; Yagoub H; Kiernan G; Ruggiero NJ; Kiernan TJ
    Expert Rev Cardiovasc Ther; 2012 Oct; 10(10):1261-72. PubMed ID: 23190065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching of platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Review of the literature and practical considerations.
    De Luca L; Capranzano P; Patti G; Parodi G
    Am Heart J; 2016 Jun; 176():44-52. PubMed ID: 27264219
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New antiplatelet agents in the treatment of acute coronary syndromes.
    Sabouret P; Taiel-Sartral M
    Arch Cardiovasc Dis; 2014 Mar; 107(3):178-87. PubMed ID: 24630752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].
    Buriakina TA; Zateĭshchikov DA
    Kardiologiia; 2012; 52(4):74-9. PubMed ID: 22839520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study.
    Deharo P; Quilici J; Bonnet G; Grosdidier C; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Platelets; 2016 Dec; 27(8):791-795. PubMed ID: 27275528
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in platelet blockers: the target is the P2Y12 receptor.
    Patel PA; Lane B; Augoustides JG
    J Cardiothorac Vasc Anesth; 2013 Jun; 27(3):620-4. PubMed ID: 23672863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adenosine receptor agonists deepen the inhibition of platelet aggregation by P2Y
    Boncler M; Wzorek J; Wolska N; Polak D; Watala C; Rozalski M
    Vascul Pharmacol; 2019 Feb; 113():47-56. PubMed ID: 30471364
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
    De Luca L; D'Ascenzo F; Musumeci G; Saia F; Parodi G; Varbella F; Marchese A; De Servi S; Berti S; Bolognese L
    EuroIntervention; 2017 Jul; 13(4):459-466. PubMed ID: 28374678
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment with P2Y12 inhibitors in non-ST-segment elevation acute coronary syndrome: Time to revise the guidelines?
    Cayla G; Collet JP; Silvain J; Montalescot G
    Arch Cardiovasc Dis; 2014 Jan; 107(1):1-3. PubMed ID: 24332911
    [No Abstract]   [Full Text] [Related]  

  • 34. A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients.
    Straub N; Beivers A; Lenk E; Aradi D; Sibbing D
    Thromb Haemost; 2014 Feb; 111(2):290-9. PubMed ID: 24154566
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a P2Y
    Amann M; Ferenc M; Valina CM; Bömicke T; Stratz C; Leggewie S; Trenk D; Neumann FJ; Hochholzer W
    Platelets; 2016 Nov; 27(7):668-672. PubMed ID: 27065056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of initial clinical presentation on clopidogrel low response.
    Landel JB; Bauters A; Delhaye C; Bonello L; Sudre A; Susen S; Bauters C; Lablanche JM; Lemesle G
    Arch Cardiovasc Dis; 2013 Nov; 106(11):593-600. PubMed ID: 24070598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors.
    Thomas MR; Storey RF
    Vascul Pharmacol; 2016 Sep; 84():25-7. PubMed ID: 27275527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Onset of optimal P2Y12-ADP receptor blockade after ticagrelor and prasugrel intake in Non-ST elevation acute coronary syndrome.
    Bonello L; Laine M; Camoin-Jau L; Noirot F; Guieu R; Dignat-George F; Paganelli F; Frere C
    Thromb Haemost; 2015 Oct; 114(4):702-7. PubMed ID: 26311415
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood.
    Mendolicchio GL; Zavalloni D; Bacci M; Corrada E; Marconi M; Lodigiani C; Presbitero P; Rota L; Ruggeri ZM
    J Thromb Haemost; 2011 Feb; 9(2):373-82. PubMed ID: 21083646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.